Phase 3 Transverse Myelitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older
- You have had your first episode of a condition where the protective coating around your brain or spinal cord nerves was attacked, and this happened within the last 3 months
- Your blood test came back positive for MOG antibodies (a specific protein found in the blood), confirmed by a specialist laboratory in Lyon
- You are able to understand what the study involves and are willing to sign a consent form agreeing to take part
- You are covered by the French social security health system
- If you are a woman who could become pregnant, you must use reliable contraception throughout the treatment and for at least 3 months after finishing treatment
Who may not be able to join:
- You have a known allergy or bad reaction to azathioprine (an immune-lowering medicine) or steroids
- You currently have an active infection (such as tuberculosis, hepatitis, herpes, or chickenpox-related virus) or an active cancer
- You have a mental health condition involving psychosis that is not controlled with medication
- Your bone marrow is not working well enough, shown by very low levels of certain blood cells (confirm with trial site)
- Your liver is not working well enough, shown by high levels of certain liver enzymes in your blood (confirm with trial site)
- Your kidneys are not working well enough, based on a measure of how well they filter your blood (confirm with trial site)
- You have received a live vaccine in the past 3 months, or plan to receive one during the trial or for 6 months after the trial ends
- You have a naturally low level of a specific enzyme called TPMT, which helps your body process certain medicines (confirm with trial site)
- You are unable to have an MRI scan — for example, because you have a pacemaker, severe fear of enclosed spaces, an allergy to the contrast dye used in MRI, or poor vein access
- You need to regularly take certain medicines that could interact with the trial treatment, including allopurinol or similar drugs, certain blood pressure medicines (ACE inhibitors), cotrimoxazole, cimetidine, or indometacin (confirm with trial site)
- You need to take a type of medicine called aminosalicylates (used for conditions like Crohn's disease or colitis)
- You are currently taking any other immune-suppressing medicine (other than the ones used in this trial) or any cancer-killing (cytotoxic) therapy
- You are currently taking part in another clinical trial involving an experimental or approved treatment
- You have recently travelled to or lived in an area where a parasitic infection called strongyloidiasis is common, and have not been tested and treated for it beforehand
- You have a rare genetic condition called Lesch-Nyhan syndrome
- You are of Asian background, due to a genetic variation that may affect how your body handles the trial medicine (confirm with trial site)
- You are pregnant, breastfeeding, or have a positive pregnancy test
- You are not able to follow the study requirements
- You are under legal guardianship or currently have restrictions on your personal freedom
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Romain MARIGNIER, MD PhD, Hospices Civils de Lyon
Phone: +334 72 35 75 22
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to first relapse (in days), comparing azathioprine-treated vs placebo-treated patients during a randomized control period of a maximum of three years.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.